Opara calls for changes at Polartechnics
15 June, 2005 by Ruth BeranJust under a week since Richard Opara stepped down from his role as interim chairman of Polartechnics (ASX:PLT) and resigned as director on June 8, his company Patonville, has served a requisition on Polartechnics to convene an Extraordinary General Meeting.
Patent granted for Solbec's Cormasine
15 June, 2005 by Ruth BeranPerth biotech Solbec Pharmaceuticals (ASX:SBP) has been granted an Australian patent covering aspects of the manufacturing, purification process and formulation of the active pharmaceutical ingredients of the company's lead compound Coramsine.
Metabolic raises $10 million
14 June, 2005 by Ruth BeranMelbourne based Metabolic Pharmaceuticals (ASX:MBP) has lifted its trading halt and reinstated its shares on the ASX's official quotation following the completion of a AUD$10 million private placement and the offer of a $10 million share purchase plan.
Metabolic shares suspended
10 June, 2005 by Ruth BeranMelbourne based Metabolic Pharmaceuticals (ASX:MBP) has suspended its shares from the ASX's official quotation in the lead-up to an announcement.
In brief: C3, GTG, Avantogen, Alchemia
09 June, 2005 by Ruth BeranClinical Cell Culture (C3, ASX:CCE) will launch CellSpray XP commercially in Europe next week at a meeting in Germany. Following the launch CellSpray XP will be available for sale in those European countries where it has regulatory approval - Austria, Denmark, Germany, Italy, The Netherlands, Switzerland and the UK.
Opara steps down as Polartechnics chair
09 June, 2005 by Ruth BeranRichard Opara has stepped down from his role as interim chairman of device company Polartechnics (ASX:PLT), and is replaced by corporate financial advisor Robert Hunter.
Biota boosted by antiviral find
09 June, 2005 by Susan WilliamsonBiota Holdings (ASX:BTA) has developed a new class of orally-effective antivirals against respiratory syncytial virus (RSV) infection that the company hopes will go to Phase I trials by 2006.
Peptech to advance anti-TNF drug after preclinical study
08 June, 2005 by Staff WritersPeptech (ASX:PTD) has claimed "significant" results in a preclinical study of its human domain antibody (dAb) therapeutic -- potency levels three times higher than the current market-leading anti-TNF drug against rheumatoid arthritis.
BioProspect claims success in termite trial
08 June, 2005 by Graeme O'NeillThe tract of bushland near Narrandera, in southern NSW, where Brisbane natural pesticide developer BioProspect (ASX:BPO) is field-trialling its promising termiticide AP778 teems with voracious termites.
Pharma-sponsored trial result reporting biased: report
07 June, 2005 by Graeme O'NeillA survey of Australian medical research specialists has found that bias and manipulation in reporting of clinical trial results are rife when the trials are sponsored by pharmaceutical companies.
Metabolic unveils obesity drug trial details
06 June, 2005 by Ruth BeranMelbourne-based Metabolic Pharmaceuticals (ASX:MBP) has clarified details of a previously announced Phase IIb trial of its anti-obesity drug AOD9604, with recruitment expected to commence in September or October this year.
Biotech stocks steadied in May: Intersuisse
06 June, 2005 by Ruth BeranWhile biotechnology stocks have suffered in the first five months of 2005 -- with the Intersuisse biotechnology index showing a 23 per cent fall since December 31 -- the index stabilised in May with a 0.28 per cent gain.
FDA advances Neuren's Phase III to next year
06 June, 2005 by Ruth BeranNZ-based Neuren (ASX:NEU) has received confirmation from the US Food and Drug Administration (FDA) that the company can bypass a previously planned Phase IIb study for its lead drug Glypromate and advance directly to a major Phase III efficacy study.
Phenomix closes US$40 million series B financing
03 June, 2005 by Ruth BeranPhenomix, based in Canberra and San Diego, has closed a US$40 million private placement of its series B preferred stock, with new US investors JPMorgan Partners and Delphi Ventures co-leading the financing.
Progen explains share price dip
03 June, 2005 by Ruth BeranBrisbane cancer-drug developer Progen (ASX:PGL) has responded to an ASX 'please explain' in response to its flagging share price, citing the expiry of listed options on May 31 and speculation of a larger than expected shortfall as possible.
